Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stock rallied over 0.04% intraday to trade at $145.71 a share on NYSE. The stock opened with a loss of -0.54% at $145.61 and touched an intraday high of $146, rising 0.04% against the last close of $145.65. The stock went to a low of $145.6 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue462.51 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) stock price is $145.71 as of the last check on Thursday, June 30. During the trading session, BHVN stock reached the peak price of $146 while $145.6 was the lowest point it dropped to.
The NYSE listed BHVN is part of Biotechnology industry that operates in the broader Health Care sector. Biohaven Pharmaceutical Holding Company Ltd. , a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States.
Dr. Vladimir Coric M.D.
Chairman, CEO & Pres
Mr. Matthew Buten
Chief Financial Officer
Ms. Kimberly Gentile
Sr. VP of Clinical Operations
Dr. Elyse Stock M.D.
Chief Medical Officer
BHVN stock traded closed the last session at $145.71, which is $0.06 or 0.04% lower than its previous close of $145.65. BHVN's current trading price is 84.42% lower than its 52-week high of $151.51 where as its distance from 52-week low of 79.01% is -3.83%.
Number of BHVN employees currently stands at -. BHVN operates from 215 Church Street, New Haven, CT 06510, United States.
Official Webiste of $BHVN is: https://www.biohavenpharma.com
BHVN stock volume for the day was 902,454 shares while in the previous session number of BHVN shares traded was 892,673 . The average number of BHVN shares traded daily for last 3 months was 1.77 Million.
The percentage change in BHVN stock occurred in the recent session was 0.04% while the dollar amount for the price change in BHVN stock was $0.06.
In the recent session, the day high for BHVN stock was $146 while the low for BHVN stock touched on the day was $145.6.
The market value of BHVN currently stands at 10.38 Billion with its latest stock price at $145.71 and 70.33 Million of its shares outstanding.